Trials / Completed
CompletedNCT05569915
Project QueST 2023: Queer Survivors of Trauma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Syracuse University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking.
Detailed description
This study aims to provide a novel method for adapting and testing evidence-based expressive writing (EW) treatments for trauma-exposed sexual minority women (SMW) and gender diverse individuals. The investigators will (1) describe the development and components of the proposed EW treatments, (2) discuss our plan for evaluating acceptability and feasibility of the proposed study, (3) identify steps for characterizing preliminary efficacy of EW treatments in reducing PTSD symptom severity and hazardous drinking levels compared to control, and (4) highlight our strategy for preliminarily evaluating mediators and moderators of treatment efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Trauma Expressive Writing | Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days. |
| BEHAVIORAL | Stigma Expressive Writing | Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days. |
| BEHAVIORAL | Control | Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies. |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
- First posted
- 2022-10-06
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05569915. Inclusion in this directory is not an endorsement.